Dr Levi Garraway

Nationality
US

Year of Birth
1968

1990
Biochemical Sciences, Harvard Medical School, A.B. 

1999
Biochemistry and Molecular Pharmacology, Harvard Medical School, Ph.D. 

1999
Medicine, Harvard Medical School, M.D.

1999-2001
Massachusetts General Hospital, Internship, and Residency in Internal Medicine

2001
Dana-Farber/Partners CancerCare, Fellowship in Medical Oncology

2003
Department of Medicine, Massachusetts General Hospital, Chief Resident

2004–2005
Laboratory of William Sellers, Dana-Farber Cancer Institute, Research Fellow

2005–2007
Dana-Farber Cancer Institute, Harvard Medical School, Instructor

2007–2011
Dana-Farber Cancer Institute, Harvard Medical School, Assistant Professor of Medicine

2010–2016
Foundation Medicine, Co-Founder and Consultant

2011–2016
Dana-Farber Cancer Institute, Harvard Medical School, Associate Professor of Medicine

2017
Eli Lilly and Company, Global Oncology, Senior Vice-President

2017
Tango Therapeutics, Co-Founder

2018
Eli Lilly and Company, Senior Vice-President, Oncology R&D, and Novel Target Research

Since 2019
Roche Basel, Executive Vice-President, Head of Global Product Development and Chief Medical Officer

–

–

2002–2007
Instructor, Harvard Medical School

2005–2016
Associate Physician of Medicine, Brigham and Women’s Hospital

2006–2010
Associate Member, Cancer Program, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard

2006–2016
Member, Biological and Biomedical Sciences Graduate Program, Biological Chemistry & Molecular Pharmacology Dept., Harvard Medical School

2007–2011
Assistant Professor of Medicine, Harvard Medical School

2010–2014
Senior Associate Member, Broad Institute

2011–2016
Associate Professor of Medicine, Harvard Medical School

2014–2016
Senior Associate Member, Broad Institute

2014–2016
Institute Member, Broad Institute

2016
Investigator, Howard Hughes Medical Institute

Since 2020
Adjunct Professor, Department of Genetics, Stanford University School of Medicine

2007–2016
Consultant, Novartis Institutes for Biomedical Research

2008–2009
Consultant, Clinical & Translational Research Center, Harvard Medical School

2009–2011
Scientific Task Force, Lymphangioleiomyomatosis (LAM) Treatment Alliance

2011–2016
Member, External Scientific Advisory Board, The Ohio State University Comprehensive Cancer Center

Since 2011
Member, Board of Scientific Consultants, Memorial Sloan-Kettering Cancer Center

Since 2013
Member, External Scientific Advisory Board, MD Anderson Cancer Center

2014–2016
Chair, External Scientific Advisory Board, IGNITE Program, National Human Genome Research Institute (NHGRI)

Since 2015
Member, The V Foundation Scientific Advisory Board

2000–2003
National Medical Association

Since 2007
American Association for Cancer Research

Since 2009
American Society for Clinical Investigation

Since 2010
American Association for the Advancement of Science

2011–2013
American Society for Biochemistry and Molecular Biology

Since 2012
American Society for Clinical Oncology

Since 2015
Association of American Physicians

Since 2020
National Academy of Medicine

2003
Partners in Excellence Award

2007
NIH Director’s New Innovator Award

2009
American Society for Clinical Investigation (President, 2015)

2012
Block Award for Outstanding Cancer Research

2013
Paul Marks Prize for Cancer Research

2014
AACR-MICR Jane Cooke Wright Award

2014
Society for Melanoma Research Outstanding Investigator Award

2015
NCI Outstanding Investigator Award

2015
Association of American Physicians

2019
Academy of Fellows, American Association for Cancer Research

2019
Honorary doctorate, Feinstein Institute

2020
National Academy of Medicine

2022
Margaret J. Foti Award for Leadership and Extraordinary Achievement in Cancer Research

2022
Memorial Sloan-Kettering Medal and honorary doctorate, Gerstner/Sloan-Kettering Graduate School of Biomedical Sciences